HIGHLIGHTS OF PRESCRIBING INFORMATION
These highlights do not include all the information needed to use
PRALUENT safely and effectively. See full prescribing information for
PRALUENT.

PRALUENT® (alirocumab) injection, for subcutaneous use
Initial U.S. Approval: 2015

----------------------------RECENT MAJOR CHANGES--------------------------

Warnings and Precautions (5.1) 3/2020

---------------------------INDICATIONS AND USAGE-------------------------
PRALUENT is a PCSK9 (proprotein convertase subtilisin kexin type 9)
inhibitor antibody indicated:
• to reduce the risk of myocardial infarction, stroke, and unstable angina
  requiring hospitalization in adults with established cardiovascular disease.
  (1.1)
• as adjunct to diet, alone or in combination with other lipid-lowering
  therapies (e.g., statins, ezetimibe), for the treatment of adults with primary
  hyperlipidemia (including heterozygous familial hypercholesterolemia) to
  reduce low-density lipoprotein cholesterol LDL-C. (1.2)

---------------------DOSAGE AND ADMINISTRATION----------------------
The recommended starting dose of PRALUENT is 75 mg once every 2 weeks
administered subcutaneously, since the majority of patients achieve sufficient
LDL-C reduction with this dosage. An alternative starting dosage for patients
who prefer less frequent dosing is 300 mg once every 4 weeks (monthly).
(2.1)
If the LDL-C response is inadequate, the dosage may be adjusted to the
maximum dosage of 150 mg administered every 2 weeks. (2.1)

The recommended dose of PRALUENT in patients with HeFH undergoing
LDL apheresis is 150 mg once every 2 weeks. PRALUENT can be
administered without regard to timing of apheresis. (2.1)

DOSE FORMS AND STRENGTHS
• Injection: 75 mg/mL or 150 mg/mL solution in a single-dose pre-filled pen (3)
• Injection: 75 mg/mL or 150 mg/mL solution in a single-dose pre-filled syringe (3)

CONTRAINDICATIONS
History of a serious hypersensitivity reaction to PRALUENT. (4)

WARNINGS AND PRECAUTIONS
Allergic Reactions: Hypersensitivity reactions (e.g., pruritus, rash, urticaria),
including some serious events (e.g., hypersensitivity vasculitis, angioedema,
and hypersensitivity reactions requiring hospitalization), have been reported
with PRALUENT treatment. If signs or symptoms of serious allergic reactions
occur, discontinue treatment with PRALUENT, treat according to the standard
of care, and monitor until signs and symptoms resolve. (5.1)

ADVERSE REACTIONS
The most commonly occurring adverse reactions (≥5% of patients treated with
PRALUENT and occurring more frequently than with placebo) are
nasopharyngitis, injection site reactions, and influenza. (6.1)

To report SUSPECTED ADVERSE REACTIONS, contact Regeneron at
1-844-734-6643 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

See 17 for PATIENT COUNSELING INFORMATION and
FDA-approved patient labeling.

Revised: 09/2020

FULL PRESCRIBING INFORMATION: CONTENTS*

1 INDICATIONS AND USAGE
  1.1 Prevention of Cardiovascular Events
  1.2 Primary Hyperlipidemia (including heterozygous familial
      hypercholesterolemia)

2 DOSAGE AND ADMINISTRATION
  2.1 Dosing Information
  2.2 Important Administration Instructions

3 DOSAGE FORMS AND STRENGTHS

4 CONTRAINDICATIONS

5 WARNINGS AND PRECAUTIONS
  5.1 Allergic Reactions

6 ADVERSE REACTIONS
  6.1 Clinical Trials Experience
  6.2 Immunogenicity
  6.3 Postmarketing Experience

8 USE IN SPECIFIC POPULATIONS
  8.1 Pregnancy
  8.2 Lactation
  8.4 Pediatric Use
  8.5 Geriatric Use

8.6 Renal Impairment
8.7 Hepatic Impairment

11 DESCRIPTION

12 CLINICAL PHARMACOLOGY
  12.1 Mechanism of Action
  12.2 Pharmacodynamics
  12.3 Pharmacokinetics

13 NONCLINICAL TOXICOLOGY
  13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
  13.2 Animal Toxicology and/or Pharmacology

14 CLINICAL STUDIES
  14.1 Prevention of Cardiovascular Events
  14.2 Primary Hyperlipidemia (including heterozygous familial
      hypercholesterolemia)

16 HOW SUPPLIED/STORAGE AND HANDLING

17 PATIENT COUNSELING INFORMATION

*Sections or subsections omitted from the full prescribing information are not
listed.
1 INDICATIONS AND USAGE

1.1 Prevention of Cardiovascular Events

PRALUENT® is indicated to reduce the risk of myocardial infarction, stroke, and unstable angina requiring hospitalization in adults with established cardiovascular disease.

1.2 Primary Hyperlipidemia (including heterozygous familial hypercholesterolemia)

PRALUENT is indicated as an adjunct to diet, alone or in combination with other lipid-lowering therapies (e.g., statins, ezetimibe), for the treatment of adults with primary hyperlipidemia to reduce low-density lipoprotein cholesterol (LDL-C).

2 DOSAGE AND ADMINISTRATION

2.1 Dosing Information

The recommended starting dose of PRALUENT is 75 mg once every 2 weeks administered subcutaneously, since the majority of patients achieve sufficient LDL-C reduction with this dosage. An alternative starting dosage for patients who prefer less frequent dosing is 300 mg once every 4 weeks (monthly).

For patients receiving PRALUENT 75 mg every 2 weeks, measure LDL-C levels within 4 to 8 weeks of initiating PRALUENT. If the LDL-C response is inadequate, the dosage may be adjusted to the maximum dosage of 150 mg administered every 2 weeks. Reassess LDL-C within 4 to 8 weeks.

For patients receiving PRALUENT 300 mg every 4 weeks, measure LDL-C just prior to the next scheduled dose, since in some patients LDL-C can vary considerably between doses with this regimen [see Clinical Studies (14)]. If LDL-C reduction is inadequate, the dosage may be adjusted to 150 mg every 2 weeks, starting the new dose on the next scheduled dosing date. Reassess LDL-C within 4 to 8 weeks.

If an every-2-week dose is missed, instruct the patient to administer the injection within 7 days from the missed dose and then resume the patient’s original schedule. If the missed dose is not administered within 7 days, instruct the patient to wait until the next dose on the original schedule.

If an every-4-week dose is missed, instruct the patient to administer the injection within 7 days from the missed dose and then resume the patient’s original schedule. If the missed dose is not administered within 7 days, instruct the patient to administer the dose, starting a new schedule based on this date.

The recommended dose of PRALUENT in patients with HeFH undergoing LDL apheresis is 150 mg once every 2 weeks. PRALUENT can be administered without regard to the timing of apheresis.
2.2 Important Administration Instructions

- Provide proper training to patients and/or caregivers on the preparation and administration of PRALUENT prior to use according to the Instructions for Use. Instruct patients and/or caregivers to read and follow the Instructions for Use each time they use PRALUENT.

- Store PRALUENT in the refrigerator. Allow PRALUENT to warm to room temperature for 30 to 40 minutes prior to use. If needed, PRALUENT may be kept at room temperature up to 77°F (25°C) for a maximum of 30 days in original carton to protect from light. Do not store above 77°F (25°C). After removal from the refrigerator, PRALUENT must be used within 30 days or discarded [see How Supplied/Storage and Handling (16)].

- PRALUENT should be inspected visually for particulate matter and discoloration prior to administration. If the solution is discolored or contains visible particulate matter, the solution should not be used.

- Follow aseptic injection technique every time PRALUENT is administered.

- Administer PRALUENT by subcutaneous injection into the thigh, abdomen, or upper arm using a single-dose pre-filled pen or single-dose pre-filled syringe.

- Rotate the injection site with each injection.

- To administer the 300 mg dose, give two 150 mg PRALUENT injections consecutively at two different injection sites.

- Do NOT inject PRALUENT into areas of active skin disease or injury such as sunburns, skin rashes, inflammation, or skin infections.

- Do NOT co-administer PRALUENT with other injectable drugs at the same injection site.

3 DOSAGE FORMS AND STRENGTHS

PRALUENT is a clear, colorless to pale yellow solution available as follows:

Injection: Single-dose pre-filled pen

- 75 mg/mL
- 150 mg/mL

Injection: Single-dose pre-filled syringe

- 75 mg/mL
- 150 mg/mL

4 CONTRAINDICATIONS

PRALUENT is contraindicated in patients with a history of a serious hypersensitivity reaction to PRALUENT. Reactions have included hypersensitivity vasculitis and hypersensitivity reactions requiring hospitalization. [See Warnings and Precautions (5.1).]
5 WARNINGS AND PRECAUTIONS

5.1 Allergic Reactions

Hypersensitivity reactions (e.g., pruritus, rash, urticaria), including some serious events (e.g., hypersensitivity vasculitis, angioedema, and hypersensitivity reactions requiring hospitalization), have been reported with PRALUENT treatment. If signs or symptoms of serious allergic reactions occur, discontinue treatment with PRALUENT, treat according to the standard of care, and monitor until signs and symptoms resolve [see Contraindications (4)].

6 ADVERSE REACTIONS

The following adverse reactions are also discussed in the other sections of the labeling:

- Allergic Reactions [See Warnings and Precautions (5.1).]

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Common Adverse Reactions

The data in Table 1 are derived from 9 primary hyperlipidemia placebo-controlled trials that included 2476 patients treated with PRALUENT 75 mg and/or 150 mg every 2 weeks, including 2135 exposed for 6 months and 1999 exposed for more than 1 year (median treatment duration of 65 weeks). The mean age of the population was 59 years, 40% of the population were women, 90% were Caucasian, 4% were Black or African American, and 3% were Asian.

Adverse reactions reported in at least 2% of PRALUENT-treated patients, and more frequently than in placebo-treated patients, are shown in Table 1.

Table 1: Adverse Reactions Occurring in Greater Than or Equal to 2% of PRALUENT-Treated Patients and More Frequently Than with Placebo

<table>
<thead>
<tr>
<th>Adverse Reactions</th>
<th>Placebo (N=1276)</th>
<th>PRALUENT(^a) (N=2476)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nasopharyngitis</td>
<td>11.1%</td>
<td>11.3%</td>
</tr>
<tr>
<td>Injection site reactions(^b)</td>
<td>5.1%</td>
<td>7.2%</td>
</tr>
<tr>
<td>Influenza</td>
<td>4.6%</td>
<td>5.7%</td>
</tr>
<tr>
<td>Urinary tract infection</td>
<td>4.6%</td>
<td>4.8%</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>4.4%</td>
<td>4.7%</td>
</tr>
<tr>
<td>Bronchitis</td>
<td>3.8%</td>
<td>4.3%</td>
</tr>
<tr>
<td>Myalgia</td>
<td>3.4%</td>
<td>4.2%</td>
</tr>
<tr>
<td>Muscle spasms</td>
<td>2.4%</td>
<td>3.1%</td>
</tr>
<tr>
<td>Sinusitis</td>
<td>2.7%</td>
<td>3.0%</td>
</tr>
<tr>
<td>Cough</td>
<td>2.3%</td>
<td>2.5%</td>
</tr>
<tr>
<td>Contusion</td>
<td>1.3%</td>
<td>2.1%</td>
</tr>
<tr>
<td>Musculoskeletal pain</td>
<td>1.6%</td>
<td>2.1%</td>
</tr>
</tbody>
</table>
Adverse reactions led to discontinuation of treatment in 5.3% of patients treated with PRALUENT and 5.1% of patients treated with placebo. The most common adverse reactions leading to treatment discontinuation in patients treated with PRALUENT were allergic reactions (0.6% versus 0.2% for PRALUENT and placebo, respectively) and elevated liver enzymes (0.3% versus <0.1%).

In an analysis of ezetimibe-controlled trials in which 864 patients were exposed to PRALUENT for a median of 27 weeks and 618 patients were exposed to ezetimibe for a median of 24 weeks, the types and frequencies of common adverse reactions were similar to those listed above.

In a cardiovascular outcomes trial in which 9451 patients were exposed to PRALUENT for a median of 31 months and 9443 patients were exposed to placebo for a median of 32 months, common adverse reactions (greater than 5% of patients treated with PRALUENT and occurring more frequently than placebo) included non-cardiac chest pain (7.0% PRALUENT, 6.8% placebo), nasopharyngitis (6.0% PRALUENT, 5.6% placebo), and myalgia (5.6% PRALUENT, 5.3% placebo).

**Local Injection Site Reactions**

In a pool of placebo-controlled trials evaluating PRALUENT 75 mg and/or 150 mg administered every 2 weeks (Q2W), local injection site reactions including erythema/redness, itching, swelling, and pain/tenderness were reported more frequently in patients treated with PRALUENT (7.2% versus 5.1% for PRALUENT and placebo, respectively). Few patients discontinued treatment because of these reactions (0.2% versus 0.4% for PRALUENT and placebo, respectively), but patients receiving PRALUENT had a greater number of injection site reactions, had more reports of associated symptoms, and had reactions of longer average duration than patients receiving placebo.

In a 48-week placebo-controlled trial evaluating PRALUENT 300 mg every 4 weeks (Q4W) and 75 mg Q2W, in which all patients received an injection of drug or placebo every 2 weeks to maintain the blind, local injection site reactions were reported more frequently in patients treated with PRALUENT 300 mg Q4W as compared to those receiving PRALUENT 75 mg Q2W or placebo (16.6%, 9.6%, and 7.9%, respectively). Three patients (0.7%) treated with PRALUENT 300 mg Q4W discontinued treatment due to local injection site reactions versus no patients (0%) in the other 2 treatment groups.

In a cardiovascular outcomes trial, local injection site reactions were reported in 3.8% of patients treated with PRALUENT versus 2.1% patients treated with placebo, and led to permanent discontinuation in 26 patients (0.3%) versus 3 patients (<0.1%), respectively.

**Allergic Reactions**

Allergic reactions were reported more frequently in patients treated with PRALUENT than in those treated with placebo (8.6% versus 7.8%). The proportion of patients who discontinued treatment due to allergic reactions was higher among those treated with PRALUENT (0.6% versus 0.2%). Serious allergic reactions, such as hypersensitivity, nummular eczema, and
hypersensitivity vasculitis were reported in patients using PRALUENT in controlled clinical trials [see Warnings and Precautions (5.1)].

Liver Enzyme Abnormalities

In the primary hyperlipidemia trials, liver-related disorders (primarily related to abnormalities in liver enzymes) were reported in 2.5% of patients treated with PRALUENT and 1.8% of patients treated with placebo, leading to treatment discontinuation in 0.4% and 0.2% of patients, respectively. Increases in serum transaminases to greater than 3 times the upper limit of normal occurred in 1.7% of patients treated with PRALUENT and 1.4% of patients treated with placebo.

Low LDL-C Values

In the placebo-controlled and active-controlled primary hyperlipidemia trials using an every 2 week or every 4 week dosing interval, 914 PRALUENT-treated patients had two consecutive calculated LDL-C values <25 mg/dL, and 335 had two consecutive calculated LDL-C values <15 mg/dL. LDL-C values <25 mg/dL and <15 mg/dL were observed more frequently in patients treated with the PRALUENT 150 mg Q2W or 300 mg Q4W dosing regimens. Changes to background lipid-altering therapy (e.g., maximally tolerated statins) were not made in response to low LDL-C values in these trials, and PRALUENT dosing was not modified or interrupted on this basis.

In a cardiovascular outcomes trial, 4305 PRALUENT-treated patients had two consecutive calculated LDL-C values <25 mg/dL, and 782 had two consecutive calculated LDL-C values <15 mg/dL. Because PRALUENT dosing was decreased or discontinued in the event of two consecutive LDL-C values <15 mg/dL in this trial, the effects of prolonged very low LDL-C with PRALUENT are unknown.

In published genetic studies as well as clinical and observational trials with lipid lowering therapies, an increased risk of new onset of diabetes has been associated with lower levels of LDL-C.

6.2 Immunogenicity

As with all therapeutic proteins, there is a potential for immunogenicity with PRALUENT. The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies to PRALUENT in the studies described below with the incidence of antibodies in other studies or to other products may be misleading.

In a cardiovascular outcomes trial, 5.5% (504/9091) of patients treated with PRALUENT 75 mg and/or 150 mg every 2 weeks (Q2W) had anti-drug antibodies (ADA) detected after initiating treatment compared with 1.6% (149/9097) of patients treated with placebo. Persistent ADA responses, defined as at least 2 consecutive post-baseline samples with positive ADA separated by at least a 16-week period, were observed in 0.7% of patients treated with PRALUENT and 0.4% of patients treated with placebo. Neutralizing antibody (NAb) responses were observed in 0.5% of patients treated with PRALUENT and in <0.1% of patients treated with placebo.

Efficacy based on reductions in LDL-C was mostly similar in patients with or without ADA.
However, some patients treated with PRALUENT with persistent or neutralizing antibodies experienced attenuation in LDL-C efficacy.

A higher incidence of injection site reactions were observed in patients with treatment-emergent ADA compared to patients who were ADA negative (7.5% vs 3.6%). In a pool of ten placebo-controlled and active-controlled trials of patients treated with PRALUENT 75 mg and/or 150 mg Q2W as well as in a separate clinical study of patients treated with PRALUENT 75 mg Q2W or 300 mg every 4 weeks (including some patients with dose adjustment to 150 mg Q2W), the incidence of detecting ADA and NAb was similar to the results from the trial described above.

The long-term consequences of continuing PRALUENT treatment in the presence of ADA are unknown.

6.3 Postmarketing Experience

The following adverse reactions have been reported during postapproval use of PRALUENT. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

- General disorders and administration site conditions
  - Flu-like illness

- Allergic reactions
  - Angioedema

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Risk Summary

There are no available data on use of PRALUENT in pregnant women to inform a drug-associated risk. In animal reproduction studies, there were no effects on embryo-fetal development when rats were subcutaneously administered alirocumab during organogenesis at dose exposures up to 12-fold the exposure at the maximum recommended human dose of 150 mg every two weeks. In monkeys, suppression of the humoral immune response was observed in infant monkeys when alirocumab was dosed during organogenesis to parturition at dose exposures 13-fold the exposure at the maximum recommended human dose of 150 mg every two weeks. No additional effects on pregnancy or neonatal/infant development were observed at dose exposures up to 81-fold the maximum recommended human dose of 150 mg every two weeks. Measurable alirocumab serum concentrations were observed in the infant monkeys at birth at comparable levels to maternal serum, indicating that alirocumab, like other IgG antibodies, crosses the placental barrier. FDA’s experience with monoclonal antibodies in humans indicates that they are unlikely to cross the placenta in the first trimester; however, they are likely to cross the placenta in increasing amounts in the second and third trimester. Consider the benefits and risks of PRALUENT and possible risks to the fetus before prescribing PRALUENT to pregnant women.
In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2%-4% and 15%-20%, respectively.

Data

Animal data

In Sprague Dawley rats, no effects on embryo-fetal development were observed when alirocumab was dosed at up to 75 mg/kg/dose by the subcutaneous route on gestation days 6 and 12 at exposures 12-fold the maximum recommended human dose of 150 mg every two weeks, based on serum AUC.

In cynomolgus monkeys, suppression of the humoral immune response to keyhole limpet hemocyanin (KLH) antigen was observed in infant monkeys at 4 to 6 months of age when alirocumab was dosed during organogenesis to parturition at 15 mg/kg/week and 75 mg/kg/week by the subcutaneous route, corresponding to 13-fold and 81-fold the human exposure at the maximum recommended human dose of 150 mg every two weeks, based on serum AUC. The lowest dose tested in the monkey resulted in humoral immune suppression; therefore, it is unknown if this effect would be observed at clinical exposure. No study designed to challenge the immune system of infant monkeys was conducted. No additional embryo-fetal, prenatal or postnatal effects were observed in infant monkeys, and no maternal effects were observed, when alirocumab was dosed at up to 75 mg/kg/week by the subcutaneous route, corresponding to maternal exposure of 81-fold the exposure at the maximum recommended human dose of 150 mg every two weeks, based on serum AUC.

8.2 Lactation

Risk Summary

There is no information regarding the presence of alirocumab in human milk, the effects on the breastfed infant, or the effects on milk production. The development and health benefits of breastfeeding should be considered along with the mother’s clinical need for PRALUENT and any potential adverse effects on the breastfed infant from PRALUENT or from the underlying maternal condition. Human IgG is present in human milk, but published data suggest that breastmilk IgG antibodies do not enter the neonatal and infant circulation in substantial amounts.

8.4 Pediatric Use

Safety and efficacy in pediatric patients have not been established.

8.5 Geriatric Use

In primary hypercholesterolemia controlled trials, 1158 patients treated with PRALUENT were ≥65 years of age and 241 patients treated with PRALUENT were ≥75 years of age. In a cardiovascular outcomes trial, 2505 patients treated with PRALUENT were ≥65 years of age and 493 patients treated with PRALUENT were ≥75 years of age. No overall differences in safety or effectiveness were observed between these patients and younger patients, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.
8.6 Renal Impairment
No dose adjustment is needed for patients with mild or moderately impaired renal function. No data are available in patients with severe renal impairment. [See Clinical Pharmacology (12.3).]

8.7 Hepatic Impairment
No dose adjustment is needed for patients with mild or moderate hepatic impairment. No data are available in patients with severe hepatic impairment. [See Clinical Pharmacology (12.3).]

11 DESCRIPTION
Alirocumab is a human monoclonal antibody (IgG1 isotype) that targets proprotein convertase subtilisin kexin type 9 (PCSK9). Alirocumab is a PCSK9 inhibitor produced by recombinant DNA technology in Chinese Hamster Ovary cell suspension culture. Alirocumab consists of two disulfide-linked human heavy chains, each covalently linked through a disulfide bond to a human kappa light chain. A single N-linked glycosylation site is located in each heavy chain within the CH2 domain of the Fc constant region of the molecule. The variable domains of the heavy and light chains combine to form the PCSK9 binding site within the antibody. Alirocumab has an approximate molecular weight of 146 kDa.

PRALUENT is a sterile, preservative-free, clear, colorless to pale yellow solution for subcutaneous injection. PRALUENT 75 mg/mL or 150 mg/mL solution for subcutaneous injection in a single-dose pre-filled pen or single-dose pre-filled syringe is supplied in a siliconized 1 mL Type-1 clear glass syringe. The needle shield is not made with natural rubber latex.

Each 75 mg/mL pre-filled pen or pre-filled syringe contains 75 mg alirocumab, histidine (8 mM), polysorbate 20 (0.1 mg), sucrose (100 mg), and Water for Injection USP, to pH 6.0.

Each 150 mg/mL pre-filled pen or pre-filled syringe contains 150 mg alirocumab, histidine (6 mM), polysorbate 20 (0.1 mg), sucrose (100 mg), and Water for Injection USP, to pH 6.0.

12 CLINICAL PHARMACOLOGY
12.1 Mechanism of Action
Alirocumab is a human monoclonal antibody that binds to proprotein convertase subtilisin kexin type 9 (PCSK9). PCSK9 binds to the low-density lipoprotein receptors (LDLR) on the surface of hepatocytes to promote LDLR degradation within the liver. LDLR is the primary receptor that clears circulating LDL, therefore the decrease in LDLR levels by PCSK9 results in higher blood levels of LDL-C. By inhibiting the binding of PCSK9 to LDLR, alirocumab increases the number of LDLRs available to clear LDL, thereby lowering LDL-C levels.

12.2 Pharmacodynamics
Alirocumab reduced free PCSK9 in a concentration-dependent manner. Following a single subcutaneous administration of alirocumab 75 or 150 mg, maximal suppression of free PCSK9 occurred within 4 to 8 hours. Free PCSK9 concentrations returned to baseline when alirocumab concentrations decreased below the limit of quantitation.

12.3 Pharmacokinetics
Absorption
After subcutaneous (SC) administration of 75 mg to 300 mg alirocumab, median times to maximum serum concentrations ($t_{\text{max}}$) were 3-7 days. The pharmacokinetics of alirocumab after single SC administration of 75 mg into the abdomen, upper arm, or thigh were similar. The absolute bioavailability of alirocumab after SC administration was about 85% as determined by population pharmacokinetics analysis. A slightly greater than dose proportional increase was observed, with a 2.1-fold to 2.7-fold increase in total alirocumab concentrations for a 2-fold increase in dose from 75 mg every 2 weeks to 150 mg every 2 weeks. Monthly dose normalized exposure with 300 mg every 4 weeks treatment was similar to that of 150 mg every 2 weeks. Steady state was reached after 2 to 3 doses with an accumulation ratio up to a maximum of about 2-fold.

**Distribution**

Following IV administration, the volume of distribution was about 0.04 to 0.05 L/kg indicating that alirocumab is distributed primarily in the circulatory system.

**Metabolism and Elimination**

Specific metabolism studies were not conducted, because alirocumab is a protein. Alirocumab is expected to degrade to small peptides and individual amino acids. In clinical studies where alirocumab was administered in combination with atorvastatin or rosuvastatin, no relevant changes in statin concentrations were observed in the presence of repeated administration of alirocumab, indicating that cytochrome P450 enzymes (mainly CYP3A4 and CYP2C9) and transporter proteins such as P-gp and OATP were not affected by alirocumab.

Two elimination phases were observed for alirocumab. At low concentrations, the elimination is predominately through saturable binding to target (PCSK9), while at higher concentrations the elimination of alirocumab is largely through a non-saturable proteolytic pathway.

Based on a population pharmacokinetic analysis, the median apparent half-life of alirocumab at steady state was 17 to 20 days in patients receiving alirocumab at subcutaneous doses of 75 mg Q2W or 150 mg Q2W.

**Specific Populations**

A population pharmacokinetic analysis was conducted on data from 2799 patients. Age, body weight, gender, race, and creatinine clearance were found not to significantly influence alirocumab pharmacokinetics. No dose adjustments are recommended for these demographics.

**Pediatric**

PRALUENT has not been studied in pediatric patients [see Use in Specific Populations (8.4)].

**Renal impairment**

Since monoclonal antibodies are not known to be eliminated via renal pathways, renal function is not expected to impact the pharmacokinetics of alirocumab.

No data are available in patients with severe renal impairment.

**Hepatic impairment**
Following administration of a single 75 mg SC dose, alirocumab pharmacokinetic profiles in patients with mild and moderate hepatic impairment were similar to those in patients with normal hepatic function.

No data are available in patients with severe hepatic impairment.

Drug-Drug Interactions

The median apparent half-life of alirocumab is reduced to 12 days when administered with a statin; however, this difference is not clinically meaningful and does not impact dosing recommendations.

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

Carcinogenicity studies have not been conducted with alirocumab. The mutagenic potential of alirocumab has not been evaluated; however, monoclonal antibodies are not expected to alter DNA or chromosomes.

There were no adverse effects on surrogate markers of fertility (e.g., estrous cyclicity, testicular volume, ejaculate volume, sperm motility, or total sperm count per ejaculate) in a 6-month chronic toxicity study in sexually-mature monkeys subcutaneously administered at 5, 15, and 75 mg/kg/week at systemic exposures up to 103-fold the 150 mg every two weeks subcutaneous clinical dose based on serum AUC. In addition, there were no adverse alirocumab-related anatomic pathology or histopathology findings in reproductive tissues in rat or monkey toxicology studies at systemic exposures up to 11-fold and 103-fold respectively, in the 6-month studies, compared to clinical systemic exposure following a 150 mg every two weeks dose, based on serum AUC.

13.2 Animal Toxicology and/or Pharmacology

During a 13-week toxicology study of 75 mg/kg once weekly alirocumab in combination with 40 mg/kg once daily atorvastatin in adult monkeys, there were no effects of PRALUENT on the humoral immune response to keyhole limpet hemocyanin (KLH) after one to two months at exposures 100-fold greater than the exposure at the maximum recommended human dose of 150 mg every two weeks, based on AUC.

14 CLINICAL STUDIES

14.1 Prevention of Cardiovascular Events

Study 1 (ODYSEY OUTCOMES, NCT01663402) was a multicenter, double-blind, placebo-controlled trial in 18,924 adult patients (9462 PRALUENT; 9462 placebo) followed for up to 5 years. Patients had an acute coronary syndrome (ACS) event 4 to 52 weeks prior to randomization and were treated with a lipid-modifying–therapy (LMT) regimen that was statin-intensive (defined as atorvastatin 40 or 80 mg, or rosuvastatin 20 or 40 mg) or at maximally tolerated dose of a statin, with or without other LMT. Patients were randomized to receive either PRALUENT 75 mg once every two weeks (Q2W) or placebo Q2W. The PRALUENT 300 mg Q4W dose [see Dosage and Administration (2.1)] was not evaluated in this study.
At month 2, if additional LDL-C lowering was required based on pre-specified LDL-C criteria (LDL-C ≥50 mg/dL), PRALUENT was adjusted to 150 mg Q2W. For patients who had their dose adjusted to 150 mg Q2W and who had two consecutive LDL-C values below 25 mg/dL, down-titration from 150 mg Q2W to 75 mg Q2W was performed. Patients on 75 mg Q2W who had two consecutive LDL-C values below 15 mg/dL were switched to placebo in a blinded fashion. Approximately 2615 (27.7%) of 9451 patients treated with PRALUENT required dose adjustment to 150 mg Q2W. Of these 2615 patients, 805 (30.8%) were down-titrated to 75 mg Q2W. Overall, 730 (7.7%) of 9451 patients switched to placebo.

A total of 99.5% of patients were followed for survival until the end of the trial. The median follow-up duration was 33 months.

The mean age at baseline was 59 years (range 39-92), with 25% women, and 27% at least 65 years old. The trial population was 79% Caucasian, 3% Black, and 13% Asian; 17% identified as Hispanic/Latino ethnicity. The index ACS event was a myocardial infarction in 83% of patients and unstable angina in 17% of patients. Prior to the index ACS event, 19% had prior myocardial infarction and 23% had coronary revascularization procedures (CABG/PCI). Selected additional baseline risk factors included hypertension (65%), diabetes mellitus (25%), New York Association class I or II congestive heart failure (15%), and eGFR <60 mL/min/1.73 m² (13%). Most patients (89%) were receiving statin-intensive therapy with or without other LMT at randomization. The mean LDL-C value at baseline was 92.4 mg/dL.

PRALUENT significantly reduced the risk for the primary composite endpoint (time to first occurrence of coronary heart disease death, non-fatal myocardial infarction, fatal and non-fatal ischemic stroke, or unstable angina requiring hospitalization: p=0.0003). The results are presented in Table 2.

### Table 2: Cardiovascular Outcomes in Patients with Established Cardiovascular Disease

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>PRALUENT N=9462</th>
<th>Placebo N=9462</th>
<th>Hazard Ratio (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n (%)</td>
<td>Incidence Rate per 100 Patient Years (95% CI)</td>
<td>n (%)</td>
</tr>
<tr>
<td>Primary composite endpoint&lt;sup&gt;b&lt;/sup&gt;</td>
<td>903 (9.5%)</td>
<td>3.5 (3.3 to 3.8)</td>
<td>1052 (11.1%)</td>
</tr>
<tr>
<td>Components of the Primary Composite Endpoint&lt;sup&gt;c&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CHD death</td>
<td>205 (2.2%)</td>
<td>0.8 (0.7 to 0.9)</td>
<td>222 (2.3%)</td>
</tr>
<tr>
<td>Non-fatal MI&lt;sup&gt;d&lt;/sup&gt;</td>
<td>626 (6.6%)</td>
<td>2.4 (2.2 to 2.6)</td>
<td>722 (7.6%)</td>
</tr>
<tr>
<td>Fatal or non-fatal ischemic stroke&lt;sup&gt;d&lt;/sup&gt;</td>
<td>111 (1.2%)</td>
<td>0.4 (0.3 to 0.5)</td>
<td>152 (1.6%)</td>
</tr>
<tr>
<td>Unstable angina requiring hospitalization&lt;sup&gt;d&lt;/sup&gt;</td>
<td>37 (0.4%)</td>
<td>0.1 (0.1 to 0.2)</td>
<td>60 (0.6%)</td>
</tr>
</tbody>
</table>

**Mortality Endpoint (not statistically significant per pre-specified method to control for type I error)**

| All-cause mortality                          | 334 (3.5%)       | 1.2 (1.1 to 1.4)| 392 (4.1%)       | 1.5 (1.3 to 1.6)| 0.85 (0.73, 0.98) |

<sup>a</sup> Cox-proportional hazards model with treatment as a factor and stratified by geographic region
<sup>b</sup> Primary composite endpoint defined as: time to first occurrence of coronary heart disease death, non-fatal myocardial infarction, fatal and non-fatal ischemic stroke, or unstable angina requiring hospitalization
<sup>c</sup> Components of the Primary Composite Endpoint
<sup>d</sup> Mortality Endpoint (not statistically significant per pre-specified method to control for type I error)
The Kaplan-Meier estimates of the cumulative incidence of the primary endpoint over time is presented in Figure 1.

Figure 1: Primary Composite Endpoint Cumulative Incidence over 4 Years in ODYSSEY OUTCOMES

![Cumulative Incidence Graph]

14.2 Primary Hyperlipidemia (including heterozygous familial hypercholesterolemia)

Study 2 (ODYSSEY LONG TERM, NCT01507831) was a multicenter, double-blind, placebo-controlled trial that randomly assigned 1553 patients to PRALUENT 150 mg Q2W and 788 patients to placebo. All patients were taking maximally tolerated doses of statins with or without other lipid-modifying therapy, and required additional LDL-C reduction. The mean age was 61 years (range 18-89), 38% were women, 93% were Caucasian, 3% were Black, and 5% were Hispanic/Latino. The average LDL-C at baseline was 122 mg/dL.

The proportion of patients who prematurely discontinued study drug prior to the 24-week primary endpoint was 8% among those treated with PRALUENT and 8% among those treated with placebo.

At week 24, the treatment difference between PRALUENT and placebo in mean LDL-C percent change was -58% (95% CI: -61%, -56%; p-value: <0.0001).

For additional results see Table 3 and Figure 2.

Table 3: Mean Percent Change from Baseline and Differencea from Placebo in Lipid Parameters at Week 24 in ODYSSEY LONG TERMb

<table>
<thead>
<tr>
<th>Treatment Group</th>
<th>LDL-C</th>
<th>Total-C</th>
<th>Non-HDL-C</th>
<th>Apo B</th>
</tr>
</thead>
<tbody>
<tr>
<td>Placebo</td>
<td>8802</td>
<td>8198</td>
<td>3471</td>
<td>629</td>
</tr>
<tr>
<td>PRALUENT</td>
<td>8843</td>
<td>8343</td>
<td>3574</td>
<td>653</td>
</tr>
</tbody>
</table>

a First occurrence of specified event at any time; patients may have experienced more than one adjudicated event
b Statistical testing performed outside hierarchy; therefore not considered statistically significant
**Week 24** (Mean Percent Change from Baseline)

<table>
<thead>
<tr>
<th></th>
<th>1</th>
<th>0</th>
<th>1</th>
<th>1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Placebo</td>
<td>101</td>
<td>01</td>
<td>11</td>
<td>11</td>
</tr>
<tr>
<td>PRALUENT (150 mg)</td>
<td>-58</td>
<td>-36</td>
<td>-49</td>
<td>-50</td>
</tr>
<tr>
<td>Difference from placebo (LS Mean) (95% CI)</td>
<td>-58 (-61, -66)</td>
<td>-36 (-37, -34)</td>
<td>-50 (-52, -47)</td>
<td>-51 (-53, -48)</td>
</tr>
</tbody>
</table>

a Difference is PRALUENT minus Placebo
b A pattern-mixture model approach was used with multiple imputation of missing post-treatment values based on a patient’s own baseline value and multiple imputation of missing on-treatment values based on a model including available on-treatment values.

**Figure 2: Mean Percent Change from Baseline in LDL-C Over 52 Weeks in Patients on Maximally Tolerated Statin Treated with PRALUENT 150 mg Q2W and Placebo Q2W (ODYSSEY LONG TERM)**

Study 3 (ODYSSEY COMBO I, NCT01644175) was a multicenter, double-blind, placebo-controlled trial that randomly assigned 209 patients to PRALUENT and 107 patients to placebo. Patients were taking maximally tolerated doses of statins with or without other lipid-modifying therapy, and required additional LDL-C reduction.

The mean age was 63 years (range 39-87), 34% were women, 82% were Caucasian, 16% were Black, and 11% were Hispanic/Latino. Mean baseline LDL-C was 102 mg/dL.
The proportion of patients who prematurely discontinued study drug prior to the 24-week primary endpoint was 11% among those treated with PRALUENT and 12% among those treated with placebo.

At week 12, the mean percent change from baseline in LDL-C was -45% with PRALUENT compared to 1% with placebo, and the treatment difference between PRALUENT 75 mg Q2W and placebo in mean LDL-C percent change was -46% (95% CI: -53%, -39%).

At week 12, if additional LDL-C lowering was required based on pre-specified LDL-C criteria, PRALUENT was up-titrated to 150 mg Q2W for the remainder of the trial. The dose was up-titrated to 150 mg Q2W in 32 (17%) of 191 patients treated with PRALUENT for at least 12 weeks. At week 24, the mean percent change from baseline in LDL-C was -44% with PRALUENT and -2% with placebo, and the treatment difference between PRALUENT and placebo in mean LDL-C percent change was -43% (95% CI: -50%, -35%; p-value: <0.0001).

Studies 4 (ODYSSEY FH I, NCT01623115) and 5 (ODYSSEY FH II, NCT01709500) were multicenter, double-blind, placebo-controlled trials that, combined, randomly assigned 490 patients to PRALUENT and 245 patients to placebo. The trials were similar with regard to both design and eligibility criteria. All patients had HeFH, were taking a maximally tolerated dose of statin with or without other lipid-modifying therapy, and required additional LDL-C reduction. The diagnosis of HeFH was made either by genotyping or clinical criteria (“definite FH” using either the Simon Broome or WHO/Dutch Lipid Network criteria). The mean age was 52 years (range 20-87), 45% were women, 94% were Caucasian, 1% were Black, and 3% were Hispanic/Latino. The average LDL-C at baseline was 141 mg/dL.

Considering both trials together, the proportion of patients who prematurely discontinued study drug prior to the 24-week primary endpoint was 6% among those treated with PRALUENT and 4% among those treated with placebo.

At week 12, the treatment difference between PRALUENT 75 mg Q2W and placebo in mean LDL-C percent change was -48% (95% CI: -52%, -44%).

At week 12, if additional LDL-C lowering was required based on pre-specified LDL-C criteria, PRALUENT was up-titrated to 150 mg Q2W for the remainder of the trials. The dose was up-titrated to 150 mg Q2W in 196 (42%) of 469 patients treated with PRALUENT for at least 12 weeks. At week 24, the mean treatment difference between PRALUENT and placebo in mean LDL-C percent change from baseline was -54% (95% CI: -59%, -50%; p-value: <0.0001). The LDL-C-lowering effect was sustained to week 52.

For additional results see Table 4 and Figure 3.

Table 4: Mean Percent Change from Baseline and Differencea from Placebo in Lipid Parameters at Week 12 and Week 24 in Patients with HeFH (ODYSSEY FH I and FH II Pooled)b

<table>
<thead>
<tr>
<th>Treatment Group</th>
<th>LDL-C</th>
<th>Total-C</th>
<th>Non-HDL-C</th>
<th>Apo B</th>
</tr>
</thead>
<tbody>
<tr>
<td>Week 12 (Mean Percent Change from Baseline)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Placebo</td>
<td>5</td>
<td>4</td>
<td>5</td>
<td>2</td>
</tr>
<tr>
<td>PRALUENT (75 mg)</td>
<td>-43</td>
<td>-27</td>
<td>-38</td>
<td>-34</td>
</tr>
</tbody>
</table>
### Table: Differences from Placebo (LS Mean) (95% CI)

<table>
<thead>
<tr>
<th>Week 24 (Mean Percent Change from Baseline)</th>
<th>Placebo</th>
<th>PRALUENT (75/up 150 mg)</th>
<th>Difference from placebo (LS Mean) (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>-47</td>
<td>-54</td>
<td>(-59, -50) (-59, -50) (-39, -33) (-45, -39)</td>
</tr>
<tr>
<td></td>
<td>-30</td>
<td>-36</td>
<td>-42</td>
</tr>
<tr>
<td></td>
<td>7</td>
<td>7</td>
<td>2</td>
</tr>
</tbody>
</table>

a Difference is PRALUENT minus Placebo
b A pattern-mixture model approach was used with multiple imputation of missing post-treatment values based on a patient’s own baseline value and multiple imputation of missing on-treatment values based on a model including available on-treatment values

Study 6 (ODYSSEY HIGH FH, NCT01617655) was a multicenter, double-blind, placebo-controlled trial that randomly assigned 72 patients to PRALUENT 150 mg Q2W and 35 patients to placebo. Patients had HeFH with a baseline LDL-C ≥160 mg/dL while taking a maximally tolerated dose of statin with or without other lipid-modifying therapy. The mean age was 51
years (range 18-80), 47% were women, 88% were Caucasian, 2% were Black, and 6% were Hispanic/Latino. The average LDL-C at baseline was 198 mg/dL.

The proportion of patients who discontinued study drug prior to the 24-week primary endpoint was 10% among those treated with PRALUENT and 0% among those treated with placebo.

At week 24, the mean percent change from baseline in LDL-C was -43% with PRALUENT and -7% with placebo, and the treatment difference between PRALUENT and placebo in mean LDL-C percent change was -36% (95% CI: -49%, -24%; p-value: <0.0001).

Study 7 (ODYSSEY CHOICE I, NCT01926782) was a multicenter, double-blind, placebo-controlled trial that randomly assigned 458 patients with primary hyperlipidemia to PRALUENT 300 mg Q4W, 115 patients to PRALUENT 75 mg Q2W, and 230 patients to placebo. Patients were stratified based on whether or not they were treated concomitantly with statin.

The mean age was 61 years (range 21-88), 42% were women, 87% were Caucasian, 11% were Black, and 3% were Hispanic/Latino.

The proportion of patients who discontinued study drug prior to the 24-week primary endpoint was 12% among those treated with PRALUENT 300 mg Q4W, 14% among those treated with PRALUENT 75 mg Q2W, and 15% among those treated with placebo.

In the cohort of patients on background statin, the mean LDL-C at baseline was 113 mg/dL. At week 12, the treatment difference between PRALUENT 300 mg Q4W and placebo in mean percent change in LDL-C from baseline was -54% (97.5% CI: -61%, -48%), and the treatment difference between PRALUENT 75 mg Q2W and placebo in mean percent change in LDL-C was -44% (97.5% CI: -53%, -35%) (Figure 4).

Figure 4: Mean Percent Change from Baseline in LDL-C up to Week 12 in Patients on Concomitant Statin Treated with PRALUENT 75 mg Q2W, PRALUENT 300 mg Q4W or Placebo

* The means were estimated based on all randomized patients, with multiple imputation of missing data taking into account treatment adherence.

At week 12, if additional LDL-C lowering was required based on pre-specified LDL-C criteria, PRALUENT was adjusted to 150 mg Q2W for the remainder of the trial. The dose was adjusted
to 150 mg Q2W in approximately 20% of patients treated with PRALUENT 75 mg Q2W or 300 mg Q4W for at least 12 weeks.

At week 24, the treatment difference between initial assignment to PRALUENT 300 mg Q4W and placebo in mean percent change in LDL-C from baseline was -56% (97.5% CI: -62%, -49%; p-value: <0.0001), and the treatment difference between initial assignment to PRALUENT 75 mg Q2W and placebo in mean percent change in LDL-C from baseline was -48% (97.5% CI: -57%, -39%).

In the cohort of patients not treated with a concomitant statin, the mean LDL-C at baseline was 142 mg/dL. The treatment difference between PRALUENT and placebo were similar to the cohort of patients treated with a concomitant statin.

Study 8 (ODYSSEY ESCAPE, NCT02326220) was a multicenter, double-blind, placebo-controlled trial that randomly assigned patients with HeFH who were undergoing LDL apheresis to PRALUENT 150 mg Q2W (N=41) or placebo (N=21). Patients were treated in combination with their usual LDL apheresis schedule for 6 weeks. The mean age was 59 years (range 27-79), 42% were women, 97% were Caucasian, 3% were Black, and 0% were Hispanic/Latino. The mean LDL-C at baseline, measured before the apheresis procedure, was 181 mg/dL. The proportion of patients who discontinued study drug prior to the 6-week endpoint was 2% among those treated with PRALUENT 150 mg Q2W and 5% among those treated with placebo. At week 6, the mean percent change from baseline in pre-apheresis LDL-C was -53% in patients in the PRALUENT group compared to 1% in patients who received placebo.

Study 9 (ODYSSEY COMBO II, NCT01644188) was a multicenter, double-blind, ezetimibe-controlled trial that randomly assigned 479 patients to PRALUENT 75 mg Q2W/150 mg Q2W and 241 patients to ezetimibe 10 mg/day. Patients were taking a maximally tolerated dose of a statin and required additional LDL-C reduction.

The mean age was 62 years (range 29-88), 26% were women, 85% were Caucasian, 4% were Black, and 3% were Hispanic/Latino. Mean baseline LDL-C was 107 mg/dL.

The proportion of patients who prematurely discontinued study drug prior to the 24-week primary endpoint was 9% among those treated with PRALUENT and 10% among those treated with ezetimibe.

At week 12, the mean percent change from baseline in LDL-C was -50% with PRALUENT compared to -22% with ezetimibe, and the treatment difference between PRALUENT and ezetimibe in mean LDL-C percent change was -28% (95% CI: -32%, -23%).

At week 12, if additional LDL-C lowering was required based on pre-specified LDL-C criteria, PRALUENT was up-titrated to 150 mg Q2W for the remainder of the trial. The dose was up-titrated to 150 mg Q2W in 82 (18%) of 446 patients treated with PRALUENT for at least 12 weeks. At week 24, the mean percent change from baseline in LDL-C was -48% with PRALUENT and -20% with ezetimibe, and the treatment difference between PRALUENT and ezetimibe in mean LDL-C percent change was -28% (95% CI: -33%, -23%; p-value: <0.0001).

Study 10 (ODYSSEY MONO, NCT01644474) was a multicenter, double-blind, ezetimibe-controlled trial in patients with a moderate CV risk, not taking statins or other lipid-modifying therapies, and a baseline LDL-C between 100 mg/dL to 190 mg/dL that randomly assigned 52 patients to PRALUENT 75 mg Q2W and 51 patients to ezetimibe 10 mg/day.
The mean age was 60 years (range 45-72), 47% were women, 90% were Caucasian and 10% were Black. Mean baseline LDL-C was 140 mg/dL. The proportion of patients who prematurely discontinued study drug prior to the 24-week endpoint was 15% among those treated with PRALUENT and 14% among those treated with ezetimibe.

At week 12, the mean percent change from baseline in LDL-C was -48% with PRALUENT compared to -19% with ezetimibe, and the treatment difference between PRALUENT 75 mg Q2W and ezetimibe in mean LDL-C percent change was -29% (95% CI: -37%, -22%). At week 12, if additional LDL-C lowering was required based on pre-specified LDL-C criteria, PRALUENT was up-titrated to 150 mg Q2W for the remainder of the trial. The dose was up-titrated to 150 mg Q2W in 14 (30%) of 46 patients treated with PRALUENT for at least 12 weeks. At week 24, the mean percent change from baseline in LDL-C was -45% with PRALUENT and -14% with ezetimibe, and the treatment difference between PRALUENT and ezetimibe in mean LDL-C percent change was -31% (95% CI: -40%, -22%; p-value: <0.0001).

16 HOW SUPPLIED/STORAGE AND HANDLING

PRALUENT is a clear, colorless to pale yellow solution, supplied in single-dose pre-filled pens and single-dose pre-filled glass syringes. Each pre-filled pen or pre-filled syringe of PRALUENT is designed to deliver 1 mL of 75 mg/mL or 150 mg/mL solution.

PRALUENT is available in cartons containing 1 or 2 pre-filled pens and 1 or 2 pre-filled syringes.

<table>
<thead>
<tr>
<th>Pack Size</th>
<th>75 mg/mL Pre-filled Pen</th>
<th>150 mg/mL Pre-filled Pen</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pack of 1 pen</td>
<td>NDC 61755-020-01</td>
<td>NDC 61755-021-01</td>
</tr>
<tr>
<td>Pack of 2 pens</td>
<td>NDC 61755-020-02</td>
<td>NDC 61755-021-02</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Pack Size</th>
<th>75 mg/mL Pre-filled Syringe</th>
<th>150 mg/mL Pre-filled Syringe</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pack of 1 syringe</td>
<td>NDC 61755-022-01</td>
<td>NDC 61755-023-01</td>
</tr>
<tr>
<td>Pack of 2 syringes</td>
<td>NDC 61755-022-02</td>
<td>NDC 61755-023-02</td>
</tr>
</tbody>
</table>

Storage

Pharmacy

Store in a refrigerator at 36°F to 46°F (2°C to 8°C) in the original carton in order to protect from light.

Patient/Caregiver

Store in a refrigerator at 36°F to 46°F (2°C to 8°C) in the original carton in order to protect from light. If needed, PRALUENT may be kept at room temperature up to 77°F (25°C) for a maximum of 30 days in original carton to protect from light. Do not store above 77°F (25°C). After removal from the refrigerator, PRALUENT must be used within 30 days or discarded.
Do NOT freeze. Do NOT expose to extreme heat. Do NOT shake.

17 PATIENT COUNSELING INFORMATION

See FDA-Approved Patient Labeling (Patient Information and Instructions for Use).

Allergic Reactions

- Advise patients to discontinue PRALUENT and seek prompt medical attention if any signs or symptoms of serious allergic reactions occur.

Instructions for Administration

- Instruct patients and caregivers to read the Patient Information and Instructions for Use (IFU) before the patient starts using PRALUENT, and each time the patient gets a refill as there may be new information they need to know.

- Provide guidance to patients and caregivers on proper subcutaneous injection technique, including aseptic technique, and how to use the pre-filled pen or pre-filled syringe correctly (see Instructions for Use leaflet). Inform patients that it may take up to 20 seconds to inject PRALUENT.

- The pre-filled pen or pre-filled syringe should be allowed to warm to room temperature for 30 to 40 minutes prior to use.

- Patients and caregivers should be cautioned that the pre-filled pen or pre-filled syringe must not be re-used and instructed in the technique of proper pen and syringe disposal in a puncture-resistant container. Do not recycle the container.

REGENERON

Manufactured by:
Regeneron Pharmaceuticals, Inc.
Tarrytown, NY 10591
U.S. License # 1760

PRALUENT is a registered trademark of Regeneron Pharmaceuticals, Inc.
©2020 Regeneron Pharmaceuticals, Inc. All rights reserved.